rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Roivant Sciences Ltd.

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Arbutus Biopharma; Director and 10% owner, Immunovant; 10% owner, Axovant Gene Therapies; 10% owner, Myovant Sciences; 10% owner, Urovant Sciences.

Every Form 4 they filed

In numbers

Trades disclosed
63
Buys
44
Sells
2
Bought
$985.1M
Sold
$0
Companies
5
Companies where not an officer
5
First trade
16 Oct 2017
Last trade
1 Oct 2026
Last filed
5 Oct 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
ABUS Arbutus BiopharmaDirector, 10% owner · Biotechnology · last 1 Oct 20260 buys · 0 sells
IMVT ImmunovantDirector, 10% owner · Biotechnology · last 12 Dec 20256 buys · 0 sells
Axovant Gene Therapies10% owner · last 24 Feb 20204 buys · 0 sells
Urovant Sciences10% owner · last 27 Dec 201925 buys · 1 sell
Myovant Sciences10% owner · last 27 Dec 20199 buys · 1 sell

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Oct 2026filed 5 Oct 2026ABUS Arbutus BiopharmaBiotechnologySEC FORM 4 Code D$44.8M8,967,383 at $5.00filing
12 Dec 2025filed 12 Dec 2025IMVT ImmunovantBiotechnologySEC FORM 4 Bought$350.0M16,666,666 at $21.00filing
13 Jan 2025filed 15 Jan 2025IMVT ImmunovantBiotechnologySEC FORM 4 Bought$336.9M16,845,010 at $20.00filing
2 Oct 2023filed 4 Oct 2023IMVT ImmunovantBiotechnologySEC FORM 4 Code A$170.0M4,473,684 at $38.00filing
2 Oct 2023filed 4 Oct 2023IMVT ImmunovantBiotechnologySEC FORM 4 Bought$58.0M1,526,316 at $38.00filing
6 Oct 2022filed 7 Oct 2022IMVT ImmunovantBiotechnologySEC FORM 4 Bought$2.5M416,667 at $6.00filing
18 Oct 2021filed 20 Oct 2021ABUS Arbutus Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code C—1,164,000filing
18 Oct 2021filed 20 Oct 2021ABUS Arbutus BiopharmaBiotechnologySEC FORM 4 Code C—22,833,922filing
2 Aug 2021filed 2 Aug 2021IMVT ImmunovantBiotechnologySEC FORM 4 Code J—17,021,276filing
17 Sep 2020filed 18 Sep 2020IMVT ImmunovantBiotechnologySEC FORM 4 Code J—8,773,969filing
4 Sep 2020filed 4 Sep 2020IMVT ImmunovantBiotechnologySEC FORM 4 Bought$12.5M380,000 at $33.00filing
12 May 2020filed 14 May 2020IMVT ImmunovantBiotechnologySEC FORM 4 Code J—8,773,969filing
16 Apr 2020filed 17 Apr 2020IMVT ImmunovantBiotechnologySEC FORM 4 Bought$15.0M1,034,483 at $14.50filing
24 Feb 2020filed 27 Feb 2020Axovant Gene TherapiesSEC FORM 4 Bought$20.0M5,333,333 at $3.75filing
27 Dec 2019filed 31 Dec 2019Myovant SciencesSEC FORM 4 Sold—45,008,604filing
27 Dec 2019filed 31 Dec 2019Urovant SciencesSEC FORM 4 Sold—22,860,013filing
18 Dec 2019filed 20 Dec 2019IMVT Immunovantoption or derivative · BiotechnologySEC FORM 4 Code J$100K10,000 at $10.00filing
18 Dec 2019filed 20 Dec 2019IMVT ImmunovantBiotechnologySEC FORM 4 Code J$369.2M36,919,967 at $10.00filing
17 Dec 2019filed 18 Dec 2019Myovant SciencesSEC FORM 4 Bought$1.2M75,000 at $15.94filing
16 Dec 2019filed 18 Dec 2019Myovant SciencesSEC FORM 4 Bought$2.0M131,541 at $14.97filing

Sectors

Health Care6
Not placed40

Buys in green, sells in red, by the company’s sector.

Related people

Jay S. StoutChief Technology Officer · Chief Technology Officer at Immunovant, filing Form 4 there in the last year
Melanie GloriaChief Operating Officer · Chief Operating Officer at Immunovant, filing Form 4 there in the last year
Christopher Van TuylChief Legal Officer · Chief Legal Officer at Immunovant, filing Form 4 there in the last year
Robert A. BeardsleyDirector · Director at Arbutus Biopharma, filing Form 4 there in the last year
Roger SawhneyDirector · Director at Arbutus Biopharma, filing Form 4 there in the last year
Eric VenkerPresident & Immunovant CEO · Also traded IMVT in the last 90 days
Atul PandeDirector · Also traded IMVT in the last 90 days